apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

103
CYBERKNIFE SRS & SBRT P.Mahadev MD DNB Apollo Speciality Cancer Hospital Chennai

Upload: dr-vijay-anand-p-reddy

Post on 14-Jun-2015

266 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

CYBERKNIFE SRS & SBRT

P.Mahadev MD DNB

Apollo Speciality Cancer Hospital

Chennai

Page 2: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

MANAGEMENT AND DELIVERY OF IMAGE GUIDED HIGH DOSE RADIATION THERAPY WITH TUMOR ABLATIVE INTENT WITHIN A COURSE OF TREATMENT THAT DOES NOT EXCEED 5 DAYS

Page 3: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Higher confidence in tumor targeting

Reliable mechanisms for generating focused, sharply delineated dose distributions with a rapid dose fall off

Reliable accurate patient positioning accounting for target motion related to time dependent organ movement

IMAGE GUIDANCE AND EFFICIENT TRACKING MECHANISM

Longer times than conventional RT, hence patient comfort is an issue

Page 4: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

SRSSBRTIMRT FOR PROSTATESRT

Page 5: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 6: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

5

1

2

3

465

Page 7: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

PitchRollYaw

Page 8: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Robot is capable of delivering radiation from different 100 nodes, with each node is capable of giving a maximum 12 different beams.

Usage of these nodes depends on the treatment room constraints

Page 9: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 10: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

The table consists of 12 fixed cones and housings of Fixed and Iris Collimator

Collimator sizes(mm): 5, 7.5, 10, 12.5, 15, 20, 25, 30, 35, 40, 50, 60

Laser Sensor

Page 11: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 12: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 13: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

There are two essential features of the CyberKnife system that sets it apart from other stereotactic radiosurgery methods.

Page 14: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

radiation source is mounted on a precisely controlled industrial robot.

The image guidance system(continuous tracking system)

Eliminates the need of gating techniques and restrictive head frames

Page 15: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

The Cyberknife treatment delivery is based on the following tracking systems

6D_ Skull tracking systemFiducials tracking systemSynchrony tracking systemX_sight Spine tracking systemX_sight Lung tracking system

Page 16: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

6D_ Skull tracking system:used for intra-cranial lesions up to C2Bony anatomy of the skull is used as reference for tracking

Page 17: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 18: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Fiducial tracking system:used for soft tissues, where gold fiducials can be implanted. Minimum of 3 nos. to be implanted

Page 19: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

close proximity to the lesion to be treated

well-separated (by about 1 cm) non-overlapping on projections from the in-room x-ray imagers

Three markers are sufficient for unique spatial localization, but in practice 4-5 are often placed in case of loss or suboptimal placement of markers

Page 20: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 21: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

• 790 fiducials• 85% successfully placed• 2 Patients developed

pneumothorax• 6 fiducials migrated- 3 in

lung, 2 in liver& 1 in prostate

Page 22: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 23: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 24: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 25: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 26: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 27: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 28: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 29: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 30: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 31: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 32: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Respiratory-induced motion of tumors causes significant targeting uncertainty Lung, liver, pancreas, Prostate,kidney

Traditional radiation therapy margins are not optimized for high-dose radiosurgery

Page 33: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 34: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Imaging and Tumor TargetingTraditional IGRT daily set-up imaging maybe inadequate for sub-millimeter accuracy

ImmobilizationBreath Holding

Page 35: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Imaging and Tumor TargetingTraditional IGRT daily set-up imaging maybe inadequate for sub-millimeter accuracy

ImmobilizationBreath HoldingGating

Page 36: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

option for dynamic tracking without the use of implanted fiducials.

Tumor localization is accomplished using auto- mated real-time image segmentation of the in-room x-ray images based on the contrast of the tumor itself.

Page 37: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

best used for lesions with sufficient contrast in density from the surrounding anatomy to be clearly visualized on both of the in-room x-ray imagers, i.e., those located in the lung periphery at least 1.5 cm in size, and that do not overlap other dense anatomical structures, such as the spine, diaphragm, and heart in the projection views

Page 38: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Two features to form the basis for accuracy

Fiducials, implanted prior to treatment

Optical markers on a special patient vest

Page 39: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Prior to treatment start: creation of dynamic correlation model

Markers are monitored in real time by a camera system

Imaging system takes positions of fiducials at discrete points of time

Page 40: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Prior to treatment start: creation of dynamic correlation model

Markers are monitored in real time by a camera system

Imaging system takes positions of fiducials at discrete points of time

time

disp

lace

men

t

disp

lace

men

t

time

Page 41: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

This process repeats throughout the treatment, updating and correcting beam delivery based upon the patient’s current breathing pattern

time

disp

lace

men

t

disp

lace

men

t

time

Page 42: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 43: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 44: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 45: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 46: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 47: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

X-sight Spine tracking system:used to track spine lesions which are close to spine from C1 to L5&sacrum

Uses the bony anatomy of spine to track the tumors in close relation to spine eliminating the need for fiducials

X-sight spine is now possible in prone position as well

Page 48: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 49: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

The appropriate tracking method has to be chosen during planning itself

No treatment is possible without planning and proper tracking method

Page 50: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Treatment planning is done on the CT images of slice thickness 1mm acquired at 125 kV and 400 mAs with a pixel size of 512 x 512

MRI, PET and 3D-Angio images can be used to fuse with the primary CT images for target and OAR delineation

Page 51: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Planning System (MultiPlan) uses inverse planning algorithm with following options1. Conformal Planning2. Sequential optimizationThe system provides the user the option of using either ray tracing method or Monte Carlo

Page 52: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

The mechanical accuracy of the system is 0.12 mm , according to Accuray

The system maintains sub-millimeter tracking accuracy, if the patient positions are within the following limitsLeft / Right (Lat) 10 mmAnt/ Post (Ver) 10 mmSup/ Inf ( Long) 10 mmRoll (Left / Right) 10

Pitch (Head Up / Down) 10

Yaw ( C.W / C.C.W) 30

Page 53: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

The Robot will correct its position if the off set values are with in the specified limits

The robot will trigger an Emergency Stop outside of these tolerances

Page 54: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 55: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 56: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 57: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 58: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Gamma knife, X-knife are probably as good.

May have an advantage for larger lesions requiring multiple fractions- meningioma, acoustic schwanomma etc

More patient friendly(frame)Continuous image guidance

Page 59: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

T1&T2 NSCLC – inoperable or medical contraindication or patient refuses surgery, ideal lesion <3cm & peripheral location

oligometastasis

Page 60: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 61: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 62: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 63: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 64: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 65: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

in a uniform population of medically inoperable patients with peripherally located early lung cancer, the RTOG 0236 study dem- onstrated 98% local control (within the primary tumor) and 87% local-regional control (within the ipsilateral lobe, hilum, and mediastinum) at 3 years with an intensive regimen of 60 Gy in 3 fractions

Page 66: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 67: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

RADIOBIOLOGICAL RATIONALE: LOW APLHA/BETA RATIO

GOOD RESULTS OBTAINED WITH HDR brachytherapy

LESS INVASIVE THAN BRACHYTHERAPY

Page 68: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 69: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 70: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 71: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Ju AW et al :Radiat oncol jan201341 pts intermediate riskMedian fu 21 mo99% biochemical PFSNo gr3/4 bladder or bowel morbidityNo significant change in sexual QOL

Page 72: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 73: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 74: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 75: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

BRACHYTHERAPY: 10/10.5 Gy x3 over 24 hours, each fraction 8 hours apart

BED : 130/142 GySBRT : 7.25 Gy x5 over 5 daysBED: 123 Gy

Page 76: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

T1 T2 PSA<10 PSA>10 GS<7 GS>7 TOTAL

HDR 30 22 35 17 40 12 52

CK 34 32 40 16 35 31 66

IMRT/IGRT

94 186 94 186 126 154 280

Page 77: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

MEDIAN FU 2 YR BIOCHEMICAL PFS

MEDIAN PSA NADIR

HDR 22 MONTHS 94% 0.8

CK 16 MONTHS 96% 1.0

IMRT/IGRT 48 MONTHS 89% 0.9

Page 78: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 79: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 80: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Fiducials placed at surgeryOne planning CT with oral and IV contrast

1000cGy to +ve margins 3-4 weeks post OP

5040cGy 5-6 field IMRT6-8 weeks postOPConcurrent XelodaAdjuvant Gemcitabine

Page 81: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 82: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 83: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 84: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 85: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 86: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 87: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 88: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Intramedullary spinal cord AVM’s onlyNot amenable to microsurgical excision/embolisation

symptomatic

Page 89: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Neurologic examinationMRIConventional 2D spinal angio

Page 90: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Spine tracking1.25 mm contrast enhanced axial CTTarget volume traced on CT in cojunction with:MRI

2D/3D spinal angio

Page 91: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

24 patients15 males 9 femalesTime from diagnosis to SRS:7.8 yrsMean age at SRS 34 YrsPresentation :12 hemorrhages

12 had progressive pain or myelopathy secondary to steal or venous congestion

Page 92: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

13 cervical8 thoracic3 conus medullaris

Page 93: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Target volume :2.8cc(0.26-15 cc)Marginal nidus dose :2050cGy(1600-2100)

Prescription isodose line:79%(68-90%)Dmax:2580cGyFractions:1 to 4

Page 94: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Angiographic outcome:significant AVM reduction in all patients >1yr post SRS

6 of 19 patients obliterateNo angio done in 5 patientsClinical outcome:no further hemorrhages

Page 95: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 96: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 97: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

3 PATIENTS28 YRS OLD LADY EMBOLISATION DONE TWICE PRESENTED WITH SEVERE PAIN IN THE POPLITEAL FOSSA AND CALF REGION

56 YEARS OLD LADY WITH SUDDEN ONSET OF MYELOPATHY

BOTH THE PATIENTS RESPONDED WELL25 yr old young man, repeated embolisations done,had no improvement

Page 98: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 99: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md
Page 100: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Current prescription dose to nidus is 2000 cGy in 2 sessions to larger lesions & 16-18 Gy for small (<0.7 cc) AVM

radiosurgery is a reasonable option in most type II spinal cord AVMs

Page 101: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Gerszten et al., Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution Volume 32,

Number 2, pp 193–199, 2007

500 cases of spinal metastases treated by CyberKnife® Radiosurgery at

the University of Pittsburgh

73 cervical, 212 thoracic, 112 lumbar, and 103 sacral lesions

Long-term pain improvement occurred in 290 of 336 cases (86%)

Long-term tumor control in 90% of lesions treated with radiosurgery as a primary treatment modality

Long-term tumor control in 88% of lesions that failed other therapies

Page 102: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md

Stereotactic radiosurgery is not a substitute to surgery but an alternative when indicated

SBRT is becoming a component in the multidisciplinary treatment of Cancer

In selected cases, SBRT may prove to be a curative modality of treatment in early cancers

Page 103: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md